-$0.07 Earnings Per Share Expected for BioTime, Inc. (BTX) This Quarter

Equities research analysts expect BioTime, Inc. (NASDAQ:BTX) to post ($0.07) earnings per share for the current fiscal quarter, according to Zacks. Four analysts have provided estimates for BioTime’s earnings, with the highest EPS estimate coming in at ($0.05) and the lowest estimate coming in at ($0.08). BioTime reported earnings of ($0.09) per share in the same quarter last year, which suggests a positive year-over-year growth rate of 22.2%. The firm is scheduled to report its next quarterly earnings report on Thursday, May 9th.

According to Zacks, analysts expect that BioTime will report full year earnings of ($0.24) per share for the current financial year, with EPS estimates ranging from ($0.32) to ($0.13). For the next financial year, analysts anticipate that the firm will report earnings of ($0.24) per share, with EPS estimates ranging from ($0.33) to ($0.08). Zacks’ EPS averages are an average based on a survey of research analysts that cover BioTime.

BTX has been the subject of several research reports. Dawson James reaffirmed a “buy” rating on shares of BioTime in a research report on Thursday, February 7th. HC Wainwright reissued a “buy” rating on shares of BioTime in a report on Thursday, February 21st.

Shares of NASDAQ BTX traded down $0.02 during midday trading on Friday, hitting $1.31. 3,633,675 shares of the company’s stock traded hands, compared to its average volume of 1,059,151. BioTime has a 1 year low of $0.66 and a 1 year high of $2.81.

About BioTime

BioTime, Inc, a clinical-stage biotechnology company, focuses on developing and commercializing products addressing degenerative diseases based on pluripotent stem cells and HyStem cell/drug delivery platform technologies primarily in the United States and Israel. The company's lead product candidates include OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa multicenter trial for the treatment of the dry age-related macular degeneration; and Renevia, a facial aesthetics product that is in pivotal clinical trial for the treatment of HIV-associated facial lipoatrophy.

Read More: Is the Dow Jones Industrial Average (DJIA) still relevant?

Get a free copy of the Zacks research report on BioTime (BTX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for BioTime Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioTime and related companies with MarketBeat.com's FREE daily email newsletter.